PR92370

GAITHERSBURG, Md., Oct. 16, 2021 /PRNewswire=KYODO JBN/ --

Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing

and commercializing next-generation vaccines for serious infectious diseases,

today announced that Vivek Shinde, M.D., Vice President, Clinical Development,

will deliver a presentation during the World Vaccine Congress Europe 2021

(https://c212.net/c/link/?t=0&l=en&o=3325009-1&h=1394430246&u=https%3A%2F%2Fwww.terrapinn.com%2Fconference%2Fworld-vaccine-congress-europe%2Findex.stm&a=World+Vaccine+Congress+Europe+2021).

A topic of discussion will be Novavax' COVID-NanoFlu(TM) Combination

Vaccine, which combines the company's recombinant nanoparticle protein-based

COVID-19 and NanoFlu(TM) vaccine candidates with Matrix-M(TM) adjuvant in a

single formulation.

Logo - https://mma.prnewswire.com/media/1506866/Novavax_High_Res_Logo.jpg

Session details are as follows:

Date:        Wednesday, October 20, 2021

Time:        11:30 a.m. -- 12:00 p.m. Central European Time (CET) / 5:30 a.m. --

                 6:00 a.m. Eastern Daylight Time (EDT)

Title:         Update on Novavax' NanoFlu vaccine and COVID-19-NanoFlu Combination

                 Vaccine development

Novavax Participant: Vivek Shinde, M.D., Vice President, Clinical Development

For more information or to register, visit the Congress website

(https://c212.net/c/link/?t=0&l=en&o=3325009-1&h=3461158481&u=https%3A%2F%2Fwww.terrapinn.com%2Fconference%2Fworld-vaccine-congress-europe%2Findex.stm&a=Congress+website).  

About Novavax

Novavax, Inc. (Nasdaq: NVAX) is a biotechnology company that promotes improved

health globally through the discovery, development and commercialization of

innovative vaccines to prevent serious infectious diseases. The company's

proprietary recombinant technology platform combines the power and speed of

genetic engineering to efficiently produce highly immunogenic nanoparticles

designed to address urgent global health needs. Novavax is conducting

late-stage clinical trials for NVX-CoV2373, its vaccine candidate against

SARS-CoV-2, the virus that causes COVID-19. NanoFlu(TM), its quadrivalent

influenza nanoparticle vaccine, met all primary objectives in its pivotal Phase

3 clinical trial in older adults. Both vaccine candidates incorporate Novavax'

proprietary saponin-based Matrix-M(TM) adjuvant to enhance the immune response

and stimulate high levels of neutralizing antibodies.

For more information, visit www.novavax.com and connect with us on

Twitter (https://c212.net/c/link/?t=0&l=en&o=3325009-1&h=2072522266&u=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D3158017-1%26h%3D500821283%26u%3Dhttps%253A%252F%252Ftwitter.com%252FNovavax%26a%3DTwitter&a=Twitter) and LinkedIn (https://c212.net/c/link/?t=0&l=en&o=3325009-1&h=1813672409&u=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D3158017-1%26h%3D3702938248%26u%3Dhttps%253A%252F%252Fwww.linkedin.com%252Fcompany%252Fnovavax%252F%26a%3DLinkedIn&a=LinkedIn).

Contacts:

Investors

Novavax, Inc.

Erika Schultz | +1 240-268-2022

ir@novavax.com

Solebury Trout

Alexandra Roy | +1 617-221-9197

aroy@soleburytrout.com

Media

Ali Chartan | +1 240-720-7804

Laura Keenan Lindsey | +1 202-709-7521

media@novavax.com

SOURCE: Novavax, Inc.